[치유와 동행] We provide free support for rare diseases and low-income people.

Urgent: New Hope for Rare Disease Patients Facing Obesity Challenges – A Groundbreaking Treatment Program Launches in Korea

Seoul, South Korea – February 9, 2026 – In a significant development for healthcare accessibility, the Korea Association for Rare and Incurable Diseases (KARD) today announced a collaborative initiative to provide crucial obesity treatment support to patients battling both rare diseases and financial hardship. This public-private partnership, involving Novo Nordisk Korea, the Community Chest of Korea, and the Korean Society of Obesity, promises to address a critical gap in care for a vulnerable population. This is breaking news with the potential to reshape treatment access for hundreds.

Addressing a Double Burden: Rare Diseases and Obesity

Obesity, recognized as a precursor to chronic conditions like diabetes, hypertension, and dyslipidemia, often presents an additional challenge for individuals living with rare diseases. Many rare disease patients experience appetite dysregulation or metabolic abnormalities that contribute to weight gain, yet face significant barriers to accessing effective treatment. The new program directly confronts this issue, acknowledging that managing obesity is often a long-term endeavor requiring both lifestyle adjustments and medical intervention.

The Program Details: Wegovy Free Fill Pens for 300 Patients

Approximately 300 patients diagnosed with rare diseases accompanied by obesity – including conditions like Prader-Willi syndrome and Angelman syndrome – and obese patients from low-income families will receive a 12-month supply of ‘Wegovy Free Fill Pen’ at no cost. Patient selection will be based on medical assessments conducted by participating hospital staff, with final decisions made through a comprehensive review of rare disease diagnosis, obesity status, and financial require. Beyond simply providing medication, the program emphasizes continuous treatment management to ensure optimal outcomes.

Industry and Association Leaders Weigh In

Casper Rosseil Poulsen, CEO of Novo Nordisk Korea, highlighted the disparities in treatment access linked to socioeconomic factors, stating that the partnership aims to ensure patients “do not offer up treatment due to environmental constraints.” Kim Min-seon, president of the Korean Society of Obesity, emphasized the importance of medical intervention and long-term management for obesity, particularly for those with rare diseases or limited resources. Kim Jae-hak, president of KARD, underscored the program’s practical support for patients burdened by the combined challenges of rare diseases and obesity, hoping it will bring meaningful change to those previously overlooked.

Nationwide Reach: Participating Medical Institutions

The program will be implemented through a network of approximately 13 medical institutions across Korea, including Korea University Anam Hospital, Myongji Hospital, Soonchunhyang University Bucheon Hospital, and Keimyung University Dongsan Hospital. A complete list of participating organizations and the program’s official launch schedule will be published on the KARD’s official website.

This initiative represents a powerful example of collaborative action to address a complex healthcare need. By bridging the gap between pharmaceutical innovation, charitable support, and medical expertise, the Korea Association for Rare and Incurable Diseases is paving the way for a more equitable and accessible healthcare system, ensuring that even the most vulnerable patients receive the care they deserve. For ongoing updates and further information on rare disease advocacy and treatment advancements, continue to check back with archyde.com.